HPV DNA testing in cervical cancer screening - Results from women in a high-risk province of Costa Rica

被引:411
|
作者
Schiffman, M
Herrero, R
Hildesheim, A
Sherman, ME
Bratti, M
Wacholder, S
Alfaro, M
Hutchinson, M
Morales, J
Greenberg, MD
Lorincz, AT
机构
[1] NCI, Interdisciplinary Studies Sect, Environm Epidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD 20852 USA
[2] Int Agcy Res Canc, F-69372 Lyon, France
[3] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA
[4] Costa Rican Social Secur Adm, San Jose, Costa Rica
[5] Brown Univ, Women & Infants Hosp, Providence, RI USA
[6] Omnia, Blue Bell, PA USA
[7] Digene Corp, Silver Spring, MD USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2000年 / 283卷 / 01期
关键词
D O I
10.1001/jama.283.1.87
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Human papillomaviruses (HPVs) are known to cause most cervical cancer worldwide, but the utility of HPV DNA testing in cervical cancer prevention has not been determined. Objective To provide comprehensive data on the screening performance of HPV testing for the most common carcinogenic types, at different levels of analytic sensitivity. Design Laboratory analysis conducted during 1993-1995, using 3 cytologic techniques and cervicography, followed by colposcopic examination of women with any abnormal cervical finding, to detect all high-grade intraepithelial lesions and cancer (reference standard of clinically significant disease). The HPV testing was performed subsequently with masking regarding clinical findings. Setting Guanacaste Province, Costa Rica, a region with a high age-adjusted incidence of cervical cancer. Participants Of 11742 randomly selected women, 8554 nonpregnant, sexually active women without hysterectomies underwent initial HPV DNA testing using the original Hybrid Capture Tube test; a stratified subsample of 1119 specimens was retested using the more analytically sensitive second generation assay, the Hybrid Capture II test. Main Outcome Measures Receiver operating characteristic analysis of detection of cervical high-grade intraepithelial lesions and cancer by HPV DNA testing based on different cut points of positivity. Results An analytic sensitivity of 1.0 pg/mL using the second generation assay would have permitted detection of 88.4% of 138 high-grade lesions and cancers (all 12 cancers were HPV-positive), with colposcopic referral of 12.3% of women. Papanicolaou testing using atypical squamous cells of undetermined significance as a cut point for referral resulted in 77.7% sensitivity and 94.2% specificity, with 6.9% referred. Specificity of the second generation assay for positivity for high-grade lesions and cancer was 89.0%, with 33.8% of remaining HPV DNA-positive subjects having low-grade or equivocal microscopically evident lesions. The higher detection threshold of 10 pg/mL used with the original assay had a sensitivity of 74.8% and a specificity of 93.4%, Lower levels of detection with the second generation assay (<1 pg/mL) proved clinically nonspecific without gains in diagnostic sensitivity, Conclusions In this study population, a cut point of 1.0 pg/mL using the second generation assay permitted sensitive detection of cervical high-grade lesions and cancer, yielding an apparently optimal trade-off between high sensitivity and reasonable specificity for this test. The test will perform best in settings in which sensitive detection of high-grade lesions and cancer is paramount. Because HPV prevalence varies by population, HPV testing positive predictive value for detection of high-grade lesions and cancer will vary accordingly, with implications for utility relative to other cervical cancer screening methods.
引用
收藏
页码:87 / 93
页数:7
相关论文
共 50 条
  • [21] Evaluation of the SureX HPV genotyping test for the detection of high-risk HPV in cervical cancer screening
    Wei, Baojun
    Mei, Ping
    Huang, Shengkai
    Yu, Xueting
    Zhi, Tong
    Wang, Guojing
    Xu, Xiaotian
    Xiao, Lin
    Dong, Xin
    Cui, Wei
    VIROLOGY JOURNAL, 2020, 17 (01)
  • [22] Evaluation of the SureX HPV genotyping test for the detection of high-risk HPV in cervical cancer screening
    Baojun Wei
    Ping Mei
    Shengkai Huang
    Xueting Yu
    Tong Zhi
    Guojing Wang
    Xiaotian Xu
    Lin Xiao
    Xin Dong
    Wei Cui
    Virology Journal, 17
  • [24] Screening for cervical cancer: Should we test for infection with high-risk HPV?
    Meijer, CJLM
    Snijders, PJF
    van den Brule, AJC
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2000, 163 (05) : 535 - 538
  • [25] High risk HPV testing for cervical cancer screening in a Puerto Rican population
    Gustafson, Erik A.
    Rosario, Juan C. Santa
    Rios-Bedoya, Carlos
    de Socarraz, Mariano
    GYNECOLOGIC ONCOLOGY REPORTS, 2023, 48
  • [26] Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer
    U Gyllensten
    K Sanner
    I Gustavsson
    M Lindell
    I Wikström
    E Wilander
    British Journal of Cancer, 2011, 105 : 694 - 697
  • [27] Short-time repeat high-risk HPV testing by self-sampling for screening of cervical cancer
    Gyllensten, U.
    Sanner, K.
    Gustavsson, I.
    Lindell, M.
    Wikstrom, I.
    Wilander, E.
    BRITISH JOURNAL OF CANCER, 2011, 105 (05) : 694 - 697
  • [28] High-Risk HPV Testing in Primary Screening for Cervical Cancer in the Public Health System, Sao Paulo, Brazil
    Levi, Jose Eduardo
    Martins, Toni Ricardo
    Longatto-Filho, Adhemar
    Cohen, Diane Dede
    Cury, Use
    Fuza, Luiz Mario
    Villa, Luisa L.
    Eluf-Neto, Jose
    CANCER PREVENTION RESEARCH, 2019, 12 (08) : 539 - 546
  • [29] PERFORMANCE OF HIGH-RISK HPV DNA GENOTYPING FOR PRIMARY CERVICAL CANCER SCREENING AND TRIAGE, COMPARED TO CYTOLOGY.
    Chatzistamatiou, K.
    Kaufmann, A. M.
    Jansen-Duerr, P.
    Skenderi, A.
    Angelidou, S.
    Katsiki, E.
    Agorastos, T.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 971 - 971
  • [30] Clinical validation of high risk HPV DNA testing versus ThinPrep cytology for primary cervical cancer screening
    Aboul-Fotouh, Mahmoud
    Hana, Ihab
    MIDDLE EAST FERTILITY SOCIETY JOURNAL, 2013, 18 (02) : 102 - 109